home > news > detailed info

Ariceum Therapeutics Appoints Chief Business Officer

Ariceum Therapeutics

BERLIN, 7 July 2022
– Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, is pleased to announce the appointment of Serge Sagodira as Chief Business Officer. Appointed from 1 July 2022, Serge will oversee all business development aspects of the company, leveraging his considerable expertise in licensing and transactions over a 20-year career in business development within the Life Sciences sector. He will work closely with the Ariceum leadership team to establish long-term strategic and value-creating collaborations with industry leaders as well as renowned academic groups in the field of radiopharmaceuticals.

Manfred Rüdiger, PhD, Chief Executive Officer of Ariceum Therapeutics, said: “We are delighted to have attracted such a high calibre individual for this important role. Serge has direct experience in the licensing of radiopharmaceutical therapies and is very well connected in our industry bringing an international approach to the development of our business. We look forward to working together as we continue to build our pipeline for the development of novel drugs for systemic targeted radiation therapy.”

Serge Sagodira, new Chief Business Officer of Ariceum Therapeutics, added: “I am excited to be taking on this new role, working with a team of experienced industry professionals to advance products that I believe have the potential to transform the treatment of very challenging cancers and ultimately significantly improve patient outcomes. I have been following the progress of Ariceum’s lead asset with interest over recent years and I am privileged to have been given the opportunity to join the team.”

Serge joins Ariceum from Swiss pharmaceutical company, Debiopharm International SA, where he worked for almost 10 years across a number of licensing and transaction roles culminating in Director, Licensing Transactions. Under Serge’s leadership in this position, Debiopharm, which develops therapeutics and biologics in the field of oncology and antimicrobial resistance, completed licensing agreements with Merck KGaA and Takeda. Serge has also completed several in-licensing transactions of early-stage programs. In addition, Serge also spent two years as Director of Business Development at DNDi, a not-for-profit R&D organization dedicated to neglected diseases supervising the structuring of complex collaborations. Serge has a PhD in Life Sciences from the University of Tours in France.
email Robert-Rössle-Straße. 10 Building 79 13125 Berlin
Print this page
Send to a friend
News and Press Releases

NHS Foundation Trust Signs Collaboration Agreement With Automata To Automate Laboratories

University Hospital Southampton (UHS) NHS Foundation Trust has signed a commercial collaboration agreement with Automata to develop new applications for laboratory automation technology. Automata is a London based biotech company providing robotic automation solutions to the life sciences industry. Comprising proprietary hardware, single-platform software and a world-class service, Automata partners with labs to take the hassle out of automation, empowering them to achieve more reliable results faster than ever before.
More info >>

White Papers

PhlexEarchive: The Right Solution for Electronic Archiving of TMF Content

Phlexglobal Ltd

Many sponsor organizations have already recognized the value of moving from paper to electronic Trial Master Files (eTMFs). But few sponsors have taken a more holistic approach to the TMF lifecycle and looked at the entire process from study start-up through archiving of the TMF in electronic format, also known as e-archiving. The recurring value of managing, tracking, maintaining and accessing electronic files should not stop at the point of archiving. All of the challenges of managing an active paper TMF carry through to a paper archive. All of the benefits of an electronic TMF also carry through to the electronic archive. As companies look to move their compliance assets to secure, long-term storage, it is important to consider ongoing compliance requirements, security, accessibility, efficiency and costs of archiving TMF content in a digital format.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement